The U.S. Supreme Court has denied a petition from the Council for Responsible Nutrition (CRN) seeking to review a New York law that restricts the sale of certain dietary supplements to individuals under the age of 18. This decision by the nation’s highest court effectively upholds a lower court’s ruling, which had previously rejected CRN’s attempt to obtain a preliminary injunction against the legislation. The law specifically targets supplements marketed for muscle-building or weight-loss, as well as those containing ingredients such as creatine, citing concerns that their use could exacerbate eating disorders among minors.
Background of the New York Law and CRN’s Challenge
The New York legislation, enacted with the stated intention of protecting vulnerable youth, emerged from a growing concern over the potential health risks associated with certain dietary supplements, particularly for adolescents. Proponents of the law argue that these products, when marketed towards appearance-based goals, can contribute to unhealthy body image issues and disordered eating patterns. The scientific underpinning of the law is largely attributed to research conducted by the Strategic Training Initiative for the Prevention of Eating Disorders (STRIPED), a research program based at Harvard University’s T.H. Chan School of Public Health, spearheaded by researcher Bryn Austin, Ph.D.
Dr. Austin and STRIPED have asserted that the supplements in question pose inherent dangers, citing findings that they can contain undisclosed ingredients linked to serious adverse health events. In a communication with SupplySide Supplement Journal in 2022, Austin stated, "These products have been found again and again to contain a toxic brew of undisclosed ingredients linked to heart palpitations, cardiac arrest, stroke and even liver damage so extensive as to require organ transplant or resulting in death." This assertion forms a significant part of the justification for the New York law’s restrictive measures.
The Council for Responsible Nutrition, a trade association representing the dietary supplement industry, vehemently opposed the law, arguing that it was based on flawed premises and insufficient scientific evidence. CRN’s challenge to the Supreme Court was predicated on the argument that the law unfairly targets products based on their marketing claims rather than their scientifically proven effects. The organization maintained that the scientific basis for the New York law was questionable, and that Dr. Austin’s conclusions were not supported by robust, peer-reviewed research.
Chronology of Legal Proceedings
The legal battle began when CRN, along with other industry stakeholders, challenged the New York law in lower courts. Their initial bid was for a preliminary injunction to halt the law’s enforcement while the case proceeded. This request was denied by the lower court, which found that CRN had not met the legal threshold for such an injunction. The decision was subsequently appealed, leading to the case reaching the Supreme Court’s docket for consideration of a writ of certiorari, which would have compelled the Court to hear the appeal.
The Supreme Court’s decision to deny this petition means that the lower court’s ruling stands. This leaves the New York law in effect without further federal judicial review at this stage. The Supreme Court typically hears cases that present significant legal questions or conflicts among lower courts, and its refusal to hear this particular case suggests it did not deem the legal arguments presented to warrant its intervention.
Industry Reactions and Expert Opinions
The denial of the Supreme Court review has elicited strong reactions from both sides of the debate. Steve Mister, President and CEO of CRN, expressed disappointment, stating, "We are disappointed that the Supreme Court will not take this opportunity to review the serious concerns raised by New York’s law. The Court’s decision not to hear the case is not a ruling on the merits of our arguments, and it does not change our view that public-health policy should be grounded in evidence rather than assumptions about lawful products."
Mister emphasized that CRN’s advocacy efforts will continue. "The Supreme Court’s decision closes one legal avenue, but it does not resolve the underlying policy concerns. CRN will continue working with lawmakers, regulators and other stakeholders to promote responsible, evidence-based policies that protect consumers without unnecessarily restricting access to lawful dietary supplements," he added. This indicates a continued commitment to challenging similar legislation and advocating for policies based on what the industry considers sound scientific principles.
On the other side of the argument, researchers like Dr. Bryn Austin maintain their position. Critics of Dr. Austin’s work, however, accuse her of selectively presenting data. They argue that while isolated incidents of adverse events linked to supplements and their ingredients can be documented, the vast number of supplement servings consumed globally over decades points to a generally safe category of consumer products.
Supporting this view, researcher Susan Hewlings, Ph.D., published a comprehensive review in the journal Nutrients in 2023. Her findings were unequivocal: "The evidence to date does not support a causative role for dietary supplements in eating disorders." This research directly challenges the premise of the New York law and highlights a significant divergence in scientific interpretation and opinion within the field. The Nutrients article analyzed existing literature, concluding that the link between supplement use and the development or exacerbation of eating disorders is not scientifically substantiated by current research.
Broader Implications and Future Outlook
The Supreme Court’s decision has significant implications for the dietary supplement industry and regulatory landscape. It signifies a potential shift in how states can enact legislation targeting specific product categories based on perceived health risks, even in the absence of definitive scientific consensus on causation. The ruling may embolden other states to pursue similar measures, potentially leading to a patchwork of regulations across the country.
This development occurs amidst a broader trend of increasing state-level regulatory scrutiny of dietary supplements. Experts have warned that a surge of state-specific rules is far from over, creating a complex compliance environment for manufacturers and retailers. The CRN’s ongoing efforts to counter what it views as misguided legislation underscore the industry’s determination to protect its market access and product categories.
The debate centers on a fundamental tension: the precautionary principle versus the burden of proof. Proponents of the New York law, and similar measures, tend to favor a precautionary approach, enacting restrictions when potential harms are identified, even if direct causation is not definitively proven. Conversely, the supplement industry generally advocates for policies grounded in robust scientific evidence, arguing that restrictions should not be imposed without clear, irrefutable proof of harm.
CRN’s strategy moving forward will likely involve continued engagement with policymakers and regulatory bodies, aiming to educate them on the scientific evidence supporting the safety and efficacy of dietary supplements. They may also pursue alternative legal avenues or focus on public awareness campaigns to counter what they perceive as misinformation.
For consumers, particularly parents and guardians of minors, the legal landscape surrounding supplement purchases will continue to evolve. The New York law, now in effect without federal judicial impediment, serves as a precedent that other jurisdictions might consider adopting. The ongoing dialogue between scientific researchers, industry advocates, and public health officials will be crucial in shaping future policies that aim to balance consumer access to beneficial products with the imperative of protecting public health, especially for vulnerable populations. The industry’s emphasis on evidence-based policy will likely remain a core tenet of its advocacy, while public health advocates will continue to push for stricter measures where potential risks are perceived.
